共 44 条
Antiretroviral drugs
被引:142
作者:
De Clercq, Erik
[1
]
机构:
[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
关键词:
REVERSE-TRANSCRIPTASE INHIBITORS;
RESISTANT HIV-1 INFECTION;
TREATMENT-NAIVE PATIENTS;
RALTEGRAVIR RESISTANCE;
COMBINATION THERAPY;
IN-VIVO;
VIRUS;
MUTATIONS;
DISCOVERY;
INVITRO;
D O I:
10.1016/j.coph.2010.04.011
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
In October 2010, it will be exactly 25 years ago that the first antiretroviral drug, AZT (zidovudine, 3'-azido-2',3'dideoxythymidine), was described. It was the first of 25 antiretroviral drugs that in the past 25 years have been formally licensed for clinical use. These antiretroviral drugs fall into seven categories [nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (Pls), fusion inhibitors (Fls), co-receptor inhibitors (CRIs) and integrase inhibitors (INIs). The INIs (i.e. raltegravir) represent the most recent advance in the search for effective and selective anti-HIV agents. Combination of several anti-HIV drugs [often referred to as highly active antiretroviral therapy (HAART)] has drastically altered AIDS from an almost uniformly fatal disease to a chronic manageable one.
引用
收藏
页码:507 / 515
页数:9
相关论文